Oncology

Top stories of the week on Specialty Pharmacy Times from May 18 to May 22.

Acute lymphoblastic leukemia accounts for nearly 25% of cancer diagnoses in children under 15 years of age.

New approach seeks to lessen resistance to cancer drugs while mitigating adverse events.

Anti-PDL1 agent with standard chemotherapy combination will now move to multiple phase 3 studies.

Study finds benefits from reduced absenteeism and improved workplace productivity.

Economic downturn associated with cancer mortality.

Blood test predicts which patients will respond to interferon.

Black men more likely to be diagnosed with breast cancer at a younger age than white men.

Excess medical expenses, employment disability, and a drop in production at work common in cancer survivors.

Particles protected antigen from premature destruction and prompted the immune system to attack cancer cells.

Age and weight found to play a role in side effects.

Kjel Jonhson, PharmD, Vice President of Global Oncology for IMS Health, discusses changes in store for the care of cancer patients over the next decade.

Mass spectrometry reveals all proteins that repair damaged cancer DNA.

Targeting gene mutations causes stress that damages cancer cell DNA.

Treating immune-suppressing cells allows for destruction of tumors.

Study finds chronic hepatitis C has a limited impact on mortality unless the patient has other severe comorbidities.

Despite advances in pain management and palliative care, intractable cancer pain remains a significant clinical, social, and financial burden in treating the oncologic population.

A look back at the top stories on Specialty Pharmacy Times from May 4 to May 8.

Genetically determined telomere length may not influence mortality.

Particulate matter found in 8 lots of Adrucil 50 mg/mL.

Researchers find significant reduction in lung cancer-specific deaths.

Levoleucovorin is for rescue use after high-dose methotrexate therapy in bone cancer.

Cancer rates significantly greater compared with non-infected individuals.

Sandoz has introduced its ready-to-use levoleucovorin injection to the US market.

Highest uninsured rates found in patients with testicular, stomach, and cervical cancers.

BRAF mutations commonly found in melanoma also seen in subset of lung cancer patients.

Introduction of protein to pancreatic cancer cells causes them to revert back to normal.

FDA finds that infusion pump did follow quality system regulations for medical devices that ensure safe use.